0001209191-17-055830.txt : 20171004 0001209191-17-055830.hdr.sgml : 20171004 20171004162226 ACCESSION NUMBER: 0001209191-17-055830 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20171002 FILED AS OF DATE: 20171004 DATE AS OF CHANGE: 20171004 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Herberts Curt A. III CENTRAL INDEX KEY: 0001691262 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-30171 FILM NUMBER: 171121913 MAIL ADDRESS: STREET 1: 501 CANAL BLVD. STREET 2: POINT RICHMOND TECH CENTER CITY: RICHMOND STATE: CA ZIP: 94804 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SANGAMO THERAPEUTICS, INC CENTRAL INDEX KEY: 0001001233 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 680359556 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 501 CANAL BLVD STREET 2: POINT RICHMOND TECH CNTR. CITY: RICHMOND STATE: CA ZIP: 94804 BUSINESS PHONE: 5109706000 MAIL ADDRESS: STREET 1: 501 CANAL BLVD STREET 2: POINT RICHMOND TECH CNTR. CITY: RICHMOND STATE: CA ZIP: 94804 FORMER COMPANY: FORMER CONFORMED NAME: SANGAMO BIOSCIENCES INC DATE OF NAME CHANGE: 20000208 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-10-02 0 0001001233 SANGAMO THERAPEUTICS, INC SGMO 0001691262 Herberts Curt A. III C/O SANGAMO THERAPEUTICS, INC. POINT RICHMOND TECH CTR, 501 CANAL BLVD. RICHMOND CA 94804 0 1 0 0 Sr.VP & Chief Business Officer Common Stock 2017-10-02 4 M 0 5830 5.41 A 21663 D Common Stock 2017-10-02 4 S 0 5830 15.00 D 15833 D Common Stock 2017-10-02 4 M 0 5416 8.87 A 21249 D Common Stock 2017-10-02 4 S 0 5416 15.00 D 15833 D Common Stock 2017-10-02 4 M 0 3754 9.41 A 19587 D Common Stock 2017-10-02 4 S 0 3754 16.00 D 15833 D Stock Option (Right to Buy) 5.41 2017-10-02 4 M 0 5830 0.00 D 2022-12-05 Common Stock 5830 0 D Stock Option (Right to Buy) 8.87 2017-10-02 4 M 0 5416 0.00 D 2025-07-26 Common Stock 5416 4584 D Stock Option (Right to Buy) 9.41 2017-10-02 4 M 0 3754 0.00 D 2025-12-07 Common Stock 3754 33746 D All sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2017. The shares underlying the stock option are fully vested and exercisable. One-quarter (1/4) of the option shares vested and became exercisable upon completion of one (1) year of service by the Reporting Person measured from the July 27, 2015 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. One-quarter (1/4) of the option shares will vest and become exercisable upon completion of one (1) year of service by the Reporting Person measured from the December 8, 2015 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. /s/ Florence Tam, Attorney-in-Fact 2017-10-03